Q2 2026 Biotech Catalysts: Complete FDA Calendar

Every major biotech catalyst from April through June 2026 — PDUFA dates, FDA Advisory Committee meetings, Phase 3 trial readouts, and conference schedules. All entries auto-generated from the live catalyst database and refreshed every Monday.

🔄 Live Database 0 Q2 2026 catalysts April 1 – June 30, 2026 Updated weekly

Q2 2026 (April–June) is one of the busiest FDA decision quarters of the year. PDUFA dates mark the FDA's self-imposed deadline to approve or reject a New Drug Application (NDA) or Biologics License Application (BLA). Missing a key catalyst date can mean missing a 40–200% move in a single session — in either direction.

This calendar aggregates every tracked catalyst across PDUFA decisions, Advisory Committee votes, Phase 3 trial data readouts, and major biotech conferences. Probability of Approval (PoA) scores use FDA historical approval rates by application type and designation. The database updates every Monday so this page reflects the latest data.

Urgency: 🔴 Overdue 🟠 Today 🟡 This Week 🔵 This Month 🟢 Upcoming

No Q2 2026 catalysts loaded yet.

Check back — the database refreshes every Monday.

How to Use This Catalyst Calendar

Each row in the table represents a binary event — a date when a drug could be approved, rejected, or delayed. For biotech investors, these dates are the highest-volatility moments in a stock's lifecycle.

💊 PDUFA Dates

FDA's self-imposed target date to approve or issue a Complete Response Letter (CRL). The highest-stakes binary event for most small-cap biotechs.

🏛️ AdCom Meetings

Advisory Committee panel votes on whether a drug should be approved. The FDA follows AdCom recommendations the majority of the time.

🔬 Trial Readouts

Phase 3 trial data releases. Positive data can trigger NDA filing; failure can be catastrophic for single-asset biotechs. PoA scores for trials use Phase 3 historical success rates (~58%).

📊 PoA Score

Historical Probability of Approval — an evidence-based base rate, not a prediction. NDA standard = 85%, NDA priority = 90%, orphan = 93%. A prior CRL reduces PoA by ~28%.

Ready to trade these catalysts?

Understanding what these dates mean is step one. Trading them profitably — position sizing for binary events, options strategies around IV crush, reading AdCom signals — is a different skill.

How to Trade PDUFA Dates: Strategy Guide →

More Resources

PDUFA Dates Explained →
How the FDA review process works, what a CRL means, and how to read PoA scores.
How to Trade PDUFA Dates →
Position sizing, options IV crush, AdCom signals, and the most common mistakes in biotech catalyst trading.
Full Catalyst Calendar →
All upcoming PDUFA dates, AdCom meetings, trial readouts, and conferences — not just Q2.

Don't Miss a Q2 Catalyst

Get ahead of PDUFA decisions and trial readouts before the market moves.

Follow on Substack →
Nothing on this page constitutes investment advice. PDUFA dates are FDA target dates — the agency is not legally required to act by this date. Probability of Approval scores are historical base rates derived from FDA CDER data and do not account for drug-specific clinical, regulatory, or manufacturing factors. Catalyst dates may change without notice. Always do your own due diligence before making any investment decision.